Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 404

Sort by

Sort Order Select

Journal Articles

To be, or not to be

Alessandro Maria Vannucchi

Blood (2020) 135 (19): 1617–1618.

https://doi.org/10.1182/blood.2020005363

Published: 2020

Journal Articles

Safety and Efficacy of First Line Venetoclax Combinations in AML Patients Ineligible for Intensive Therapy, a Real World Data

Arie Apel, MD, Yishay Ofran, MD, Avraham Frisch, MD, Yakir Moshe, MD, Ofir Wolach, MD, Chiya Leibovitch, MD, Natalia Kreiniz, MD, Maya Koren-Michowitz, MD

Blood (2019) 134 (Supplement_1): 3902.

https://doi.org/10.1182/blood-2019-125720

Published: 2019

Journal Articles

Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial

Conrad-Amadeus Voltin, Jasmin Mettler, MD, Horst Mueller, PhD, Michael Fuchs, MD, Christian Baues, MD, Markus Dietlein, MD, Andreas Engert, MD, Peter Borchmann, MD PhD, Carsten Kobe, Paul J Bröckelmann, MD

Blood (2019) 134 (Supplement_1): 4020.

https://doi.org/10.1182/blood-2019-123641

Published: 2019

Journal Articles

Frequency of Marrow Infiltrating PD-1 Expressing CD4 Effectors Following Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma Is Prognostic for Clinical Outcome

Nouf Alrasheed, Lydia Lee, Huw Richards, William Wilson, Oliver C Cohen, MBBS, BSc, FRCPath, Selina J Chavda, Jake Henry, Andrew Furness, Melody Chin, Daria Galas-Filipowicz, Charalampia Kyriakou, Neil K Rabin, Sergio A Quezada, Kwee Yong

Blood (2019) 134 (Supplement_1): 4368.

https://doi.org/10.1182/blood-2019-126682

Published: 2019

Journal Articles

Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial

Abhishek Maiti, MBBS, Courtney D. DiNardo, MDMSc, Caitlin R. Rausch, PharmD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Maro N. Ohanian, DO, Nicholas J. Short, MD, Yesid Alvarado, MD, Christopher B. Benton, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Musa E. Yilmaz, MD, Nitin Jain, MD, Steven M. Kornblau, MD, Koji Sasaki, MD, Michael Andreeff, MD PhD, Prithviraj Bose, MD, Alessandra Ferrajoli, MD, Ghayas C. Issa, MD, Elias Jabbour, MD, Lucia Masarova, MD, Michael E. Rytting, MD, Philip A. Thompson, MBBS, Sa A Wang, MD, Sergej Konoplev, Zhining Chen, Maitrayee Goswami, Rita Maduike, Julio A Guerrero, RN, Qi Zhang, PhD, Antonio Cavazos, Helen Ma, MS, Carol A. Bivins, RN, Allison Wade, Shadiat L Adewale, Susan Tse, Robin Thomas, Kenneth Vaughan, RN, Sherry A. Pierce, BSN, BA, Jing Ning, PhD, Wei Qiao, PhD, John S. Welch, MD PhD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 2637.

https://doi.org/10.1182/blood-2019-127803

Published: 2019

Journal Articles

Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study

Jeff P. Sharman, MD, David Andorsky, MD, Jason M. Melear, MD, Sudhir Manda, MD, Bertrand M. Anz, III, MD, Kathryn S. Kolibaba, MD, Habte A Yimer, MD, John M Burke, MD, Suzanne R. Fanning, DO, Jay Courtright, MD, Miguel Islas-Ohlmayer, MD, Suman Kambhampati, MD, Abdullah Al Masud, PhD, Todd Zimmerman, Jacqueline Nielsen, PhD, Tamas Vizkelety, Dingfeng Jiang, Ian W. Flinn, MD PhD

Blood (2019) 134 (Supplement_1): 3042.

https://doi.org/10.1182/blood-2019-127408

Published: 2019

Journal Articles

Current Treatments Do Not Improve the Prognosis of Patients with Atypical CML and Unclassified MDS/MPN. a Joint Report from Fi-LMC, FIM, Gfch and GFM

Vaidie Julien, MD, Delphine Rea, MD, Sylvain Thepot, MD, Le Pluart Bruno, MD, Nathalie Gachard, PhD, Stéphanie Struski, MD, Lydia Roy, MD, Cecile Bally, MD, Jo Caers, MD PhD, Franck E Nicolini, MD PhD, Bruno Cassinat, PharmD, PhD, Eric Lippert, MD PhD, Laurence Legros, MD PhD, Raphael Itzykson, MD PhD

Blood (2019) 134 (Supplement_1): 2954.

https://doi.org/10.1182/blood-2019-127254

Published: 2019

Journal Articles

Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies

Marzia Capelletti, PhD MMSc, Jessica Liegel, MD, Maria Themeli, MD PhD, Tuna Mutis, Dina Stroopinsky, PhD, Shira Orr, PhD, Daniela Torres, Adam Morin, Gertrude Gunset, BA, Haider Ghiasuddin, Maryam Rahimian, MD, Myrna Nahas, MD, Lina Bisharat, Shufen Meng, MD, Nikhil C. Munshi, MD, Donald Kufe, MD, Jacalyn Rosenblatt, MD, Michel Sadelain, MD PhD, David E. Avigan, MD

Blood (2019) 134 (Supplement_1): 3227.

https://doi.org/10.1182/blood-2019-124944

Published: 2019

Journal Articles

MSKCC Early Experience Using Radiotherapy As a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma before CD19 CAR T Therapy

Brandon Imber, MD MA, M. Lia Palomba, MD, Carl DeSelm, MD PhD, Connie Lee Batlevi, MD PhD, Parastoo B. Dahi, MD, Sergio A. Giralt, MD, Ariela Noy, MD, Jae H. Park, MD, Craig S. Sauter, MD, Michael Scordo, MD, Gunjan L. Shah, MDMS, Michel Sadelain, MD PhD, Miguel-Angel Perales, MD, Joachim Yahalom, MD

Blood (2019) 134 (Supplement_1): 3238.

https://doi.org/10.1182/blood-2019-131449

Published: 2019

Journal Articles

Real World Chart Review of Blinatumomab to Treat Patients with High Disease Burden of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Amber C. King, PharmD, BCOP, Rachel Bolanos, PhD MPH, Kelly Velasco, PharmD, Huakang Tu, PhD, Faraz Zaman, MD, Mark B. Geyer, MD, Jae H. Park, MD

Blood (2019) 134 (Supplement_1): 5079.

https://doi.org/10.1182/blood-2019-122745

Published: 2019

Journal Articles

Biodistribution and Efficacy of L-Annamycin in a Novel Imageable AML Mouse Model

Rafal Zielinski, PhD, Krzysztof Grela, PhD, Stanislaw Skora, PhD, Rodrigo Jacamo, PhD, Izabela Fokt, PhD, Matthew Sander, Magdalena Remiszewski, PhD, Edward Felix, PhD, Meenakshi Shanmugasundaram, Malgorzata Anna Zal, MSc, Michael Andreeff, MD PhD, Waldemar Priebe, PhD, Tomasz Zal, PhD

Blood (2019) 134 (Supplement_1): 5150.

https://doi.org/10.1182/blood-2019-131977

Published: 2019

Journal Articles

Study on the Possibility of Emergency Percutaneous Coronary Intervention (PCI) in Myeloproliferative Neoplasms (MPNs) Patients with Acute Coronary Syndrome (ACS)

Ye Chen, Xiuchuan Qin, Xue Han, Beibei Bai, Yingchun Wang

Blood (2019) 134 (Supplement_1): 5375.

https://doi.org/10.1182/blood-2019-124612

Published: 2019

Journal Articles

Hydroxyurea Pharmacokinetic Profiles in Children Treated for Extreme Thrombocytosis after Total Pancreatectomy with Islet Cell Autotransplant Demonstrate Poor Absorption

Alexander A Boucher, MD, Min Dong, PhD, Anu Marahatta, PhD, Adriane Hausfeld, Thad A. Howard, MS, Jaimie D Nathan, MD, Alexander A. Vinks, PharmD, PhD FCP, Patrick T. McGann, MD, Russell E. Ware, MD PhD, Lori Luchtman-Jones, MD

Blood (2019) 134 (Supplement_1): 4893.

https://doi.org/10.1182/blood-2019-127378

Published: 2019

Journal Articles

Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1 st FLOR' Study

Allison Barraclough, Geoff Chong, Michael Gilbertson, Andrew Grigg, Leonid Churilov, Tineke Fancourt, David Ritchie, MD PhD, Rachel Koldej, Rishu Agarwal, Kate Manos, Charmaine Smith, Kristen Houdyk, Joanne Hawking, Eliza Hawkes

Blood (2019) 134 (Supplement_1): 1523.

https://doi.org/10.1182/blood-2019-123908

Published: 2019

Journal Articles

Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study

Jean-Jacques Kiladjian, MD PhD, Christoph Klade, PhD, Pencho Georgiev, MD, Dorota Krochmalczyk, MD, Liana Gercheva-Kyuchukova, MD, Miklos Egyed, Viktor Rossiev, MD, Petr Dulicek, MD, Árpád Illés, MD D.Sc, Halyna Pylypenko, MD, Lylia Sivcheva, MD, Jiri Mayer, MD, Vera Yablokova, MD, Kurt Krejcy, MD, Hans Hasselbalch, MD, Robert Kralovics, PhD, Heinz Gisslinger, MD

Blood (2019) 134 (Supplement_1): 553.

https://doi.org/10.1182/blood-2019-122233

Published: 2019

Journal Articles

Preliminary Minimal Residual Disease Analysis of the Australasian Leukaemia & Lymphoma Group (ALLG) ALL8 Study of Front-Line Blinatumomab with Chemotherapy in Adults with Ph Negative B-Cell Acute Lymphoblastic Leukaemia

Shaun Fleming, MBBS,, Nicola Venn, BSc, John Reynolds, PhD, Uyen Nguyen, John Kwan, MBBS,FRACP,FRCPA, John Moore, MDFRACP,FRCPA, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Michael F. Leahy, MBChB, FRACP, FRCPath, FRCP, Matthew Greenwood, MBBS, FRACP, FRCPA, Emma Verner, MBBS, BMedSci,FRCPA, FRACP, Ashish Bajel, MBBS, FRACP, FRCPA, Leanne Berkahn, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Rosemary Sutton, BSc MSc PhD

Blood (2019) 134 (Supplement_1): 1300.

https://doi.org/10.1182/blood-2019-132048

Published: 2019

Journal Articles

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

Ariel F Grajales-Cruz, MD, Julio Chavez, Virginia Olivia Volpe, MD, Jose Sandoval-Sus, MD, Bijal Shah, MD, Celeste Bello, MD, Lubomir Sokol, MD PhD, Shanel Fisher, Rajesh R Nair, PhD, Yun Seongseok, MD, Hayder Saeed, MD, Leidy Isenalumhe, MD, Elyce P. Turba, MSN, RN, Lisa Nodzon, PhD ARNP, AOCNP, Javier Pinilla Ibarz, MD PhD

Blood (2019) 134 (Supplement_1): 5484.

https://doi.org/10.1182/blood-2019-129260

Published: 2019

Journal Articles

ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma

Andrew D. Zelenetz, MD PhD, Pier Luigi Luigi Zinzani, MD, Henry Chan, MBChB, Christian Buske, MD PhD, Vincent Ribrag, David Cunningham, MD FRCP, FMedSci, Wojciech Jurczak, Pau Abrisqueta, MD PhD, Joanne Li, Igor Gorbatchevsky, MD, Jennifer R. Brown, MD PhD

Blood (2019) 134 (Supplement_1): 5244.

https://doi.org/10.1182/blood-2019-124326

Published: 2019

Journal Articles

AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Eliza A Hawkes, Kate Manos, MBBS, Charmaine Smith, Joanne Hawking, Stephanie O'Brien, Leonid Churilov, Joseph McKendrick, William Renwick, Andrew Grigg, Tom Witkowski, Andrew Scott, Sze-Ting Lee, Wendi Lin, Chun Fong, Carmela Rooney, Allison Barraclough, Joel Wight, Geoff Chong

Blood (2019) 134 (Supplement_1): 5332.

https://doi.org/10.1182/blood-2019-127858

Published: 2019

Journal Articles

Liposomal Daunorubicin/Cytarabine As a Bridge to Donor Lymphocyte Infusion or Allogeneic Stem Cell Transplantation for High-Risk Acute Myelogenous Leukemia

Daulath Singh, MD, Patrick Hagen, MD, Nasheed Hossain, MD, Scott E. Smith, MD PhD, Patrick J. Stiff, MD, Stephanie B. Tsai, MD MS

Blood (2019) 134 (Supplement_1): 5726.

https://doi.org/10.1182/blood-2019-129380

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

To be, or not to be

Safety and Efficacy of First Line Venetoclax Combinations in AML Patients Ineligible for Intensive Therapy, a Real World Data

Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial

Frequency of Marrow Infiltrating PD-1 Expressing CD4 Effectors Following Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma Is Prognostic for Clinical Outcome

Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial

Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study

Current Treatments Do Not Improve the Prognosis of Patients with Atypical CML and Unclassified MDS/MPN. a Joint Report from Fi-LMC, FIM, Gfch and GFM

Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies

MSKCC Early Experience Using Radiotherapy As a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma before CD19 CAR T Therapy

Real World Chart Review of Blinatumomab to Treat Patients with High Disease Burden of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Biodistribution and Efficacy of L-Annamycin in a Novel Imageable AML Mouse Model

Study on the Possibility of Emergency Percutaneous Coronary Intervention (PCI) in Myeloproliferative Neoplasms (MPNs) Patients with Acute Coronary Syndrome (ACS)

Hydroxyurea Pharmacokinetic Profiles in Children Treated for Extreme Thrombocytosis after Total Pancreatectomy with Islet Cell Autotransplant Demonstrate Poor Absorption

Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1 st FLOR' Study

Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study

Preliminary Minimal Residual Disease Analysis of the Australasian Leukaemia & Lymphoma Group (ALLG) ALL8 Study of Front-Line Blinatumomab with Chemotherapy in Adults with Ph Negative B-Cell Acute Lymphoblastic Leukaemia

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma

AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Liposomal Daunorubicin/Cytarabine As a Bridge to Donor Lymphocyte Infusion or Allogeneic Stem Cell Transplantation for High-Risk Acute Myelogenous Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only